Therapeutic targeting of circTNK2 with nanoparticles restores tamoxifen sensitivity and enhances NK cell-mediated immunity in ER-positive breast cancer
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217823 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Runxin Wu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Disease Center, General Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, …. Hauptthemen laut MEDLINE: Breast Neoplasms, Killer Cells, Natural, Tamoxifen, Nanoparticles. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Education Department of Jiangxi Province, Jiangxi Provincial Department of Science and Technology, Major Science and Technology Projects in Anhui Province.
Abstract (Originalsprache)
Endocrine resistance is a leading cause of relapse in patients with estrogen receptor (ER)-positive breast cancer (ER+ BC), with tamoxifen resistance being the most prevalent form. circTNK2, a circular RNA, is overexpressed in tamoxifen-resistant BC tissues and is correlated with poor prognosis. circTNK2 encodes a novel 487-amino acid protein, termed C-TNK2-487aa, which inhibits the recruitment of natural killer (NK) cells into BC tumors. Mechanistically, C-TNK2-487aa interacts with STAT3 and promotes STAT3 phosphorylation (p-STAT3) in ER+ BC cells. The increased p-STAT3 competes with STAT1 binding, inhibiting the formation of STAT1 homodimers that induces CXCL10 expression, ultimately leading to immune evasion. Additionally, circTNK2 RNA binds to SRSF1 and promotes tamoxifen resistance and BC tumorigenicity by activating AKT-mTOR signaling. Delivery of BC-targeting ZIF-8 nanoparticles loaded with circTNK2 antisense oligonucleotides (ASOs) and a CXCL10-encoding plasmid DNA markedly suppresses the growth of BC tumor xenografts, restores tamoxifen sensitivity, and increases CD56+ NK cell infiltration into BC tumors. Our data describe a critical role of the circTNK2-encoded peptide and its RNA in ER+ BC resistance to tamoxifen and immune evasion, providing a therapeutic vulnerability in treating tamoxifen-resistant breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Disease Center, General Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China; The Ken & Ruth Davee Department of Neurology, The Lou and Jean…
- Department of Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China; Postdoctoral Innovation Practice Base, The First Affiliated Hospital, Jiangxi Medical Colleg…
- Biotherapy Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
- Department of Breast Disease Center, General Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China.
- The Ken & Ruth Davee Department of Neurology, The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg…
- Department of Blood Transfusion, Key Laboratory of Jiangxi Province for Transfusion Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China.
Förderung
- Education Department of Jiangxi Province
- Jiangxi Provincial Department of Science and Technology
- Major Science and Technology Projects in Anhui Province
- Nanchang University
- Natural Science Foundation of Jiangxi Province Youth Project
- The major science and technology R&D Projects of Jiangxi Province
- Jiangxi Province “Ganpo Talent Program” Innovation leadership Talent
- National Natural Science Foundation of China
Zitieren
APA
Wu, R., Yu, S., Bi, A., Li, Y., Tiek, D., Yu, K., Xiong, H., Shi, Q., Mo, Z., Yu, X., Song, X., Yin, F., Wang, Y., Yi, W., Liu, M., Li, P., Hu, B., Le, A., Cheng, S. Y., & Zhou, B. (2025). Therapeutic targeting of circTNK2 with nanoparticles restores tamoxifen sensitivity and enhances NK cell-mediated immunity in ER-positive breast cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217823
Vancouver
Wu R, Yu S, Bi A, Li Y, Tiek D, Yu K, et al. Therapeutic targeting of circTNK2 with nanoparticles restores tamoxifen sensitivity and enhances NK cell-mediated immunity in ER-positive breast cancer. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217823
BibTeX
@article{Wu2025,
author = {Wu, Runxin and Yu, Shubin and Bi, Aiwei and Li, Yingliang and Tiek, Deanna and Yu, Kuai and Xiong, Haiwei and Shi, Qingfeng and Mo, Zhaohong and Yu, Xiaozhou and Song, Xiao and Yin, Fang and Wang, Yu and Yi, Wang and Liu, Mengting and Li, Penghui and Hu, Bo and Le, Aiping and Cheng, Shi-Yuan and Zhou, Boxuan},
title = {Therapeutic targeting of circTNK2 with nanoparticles restores tamoxifen sensitivity and enhances NK cell-mediated immunity in ER-positive breast cancer},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217823}
}
EUVIMED